肿瘤细胞治疗研究
英文原题：CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.
本综述探讨了将 CAR-T 细胞疗法与重建性肿瘤外科手术整合，用于治疗外周实体瘤，包括黑色素瘤、肉瘤、乳腺癌和头颈部癌。
本综述探讨将嵌合抗原受体（CAR）-T细胞疗法与重建肿瘤外科手术相结合，用于治疗外周实体瘤，包括黑色素瘤、肉瘤、乳腺癌和头颈部癌。尽管CAR-T细胞已在血液肿瘤中显示出有效性，但其在实体瘤中的疗效因肿瘤异质性、免疫抑制和细胞浸润不良而受限。涉及局部递送CAR-T细胞、改进CAR设计以及靶向抗原选择（如HER2、MUC1、GD2和B7-H3）的新兴方法，被讨论为增强治疗结局的有前景策略。本综述重点介绍的临床研究表明局部肿瘤控制得到改善，并具有优化手术切除的潜力。此外，将CAR-T疗法与手术相结合可能减少肿瘤复发，并对重建结局产生积极影响。总体而言，本综述强调CAR-T细胞疗法作为肿瘤外科中一种潜在辅助治疗，强调跨学科方法对于改善实体瘤管理中患者结局的重要性。
This review addresses the integration of chimeric antigen receptor (CAR)-T cell therapy with reconstructive oncologic surgery in treating peripheral solid tumors, including melanoma, sarcomas, breast cancer, and head and neck cancers. While CAR-T cells have demonstrated effectiveness in blood cancers, their efficacy in solid tumors has been limited due to tumor heterogeneity, immune suppression, and poor cellular infiltration. Emerging approaches involving localized CAR-T cell delivery, improved CAR design, and targeted antigen selection (such as HER2, MUC1, GD2, and B7-H3) are discussed as promising strategies to enhance therapeutic outcomes. Clinical studies highlighted in this review indicate improved local tumor control and potential to optimize surgical resections. Additionally, combining CAR-T therapy with surgery may reduce tumor recurrence and positively influence reconstructive outcomes. Overall, this review underscores CAR-T cell therapy as a potential adjunctive treatment in oncologic surgery, emphasizing the importance of interdisciplinary approaches to improve patient outcomes in solid tumor management.
MEMBER ACCOUNT
登录成功会直接打开下一页。
